NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO™ (Respiratory Syncytial Virus Vaccine), the company’s bivalent ...

Already with an approval in hand for older adults, Pfizer’s Abrysvo has become the first vaccine for pregnant women to protect their newborns against respiratory syncytial virus (RSV). The FDA has ...

Tuesday, Pfizer Inc PFE released top-line immunogenicity and safety data from the ongoing pivotal Phase 3 MONeT trial, evaluating a single dose of Abrysvo versus placebo in adults 18 to 59 years of ...

As Pfizer races to grow the respiratory syncytial virus (RSV) vaccine market along with rival GSK, the company has been looking to expand its vaccine's reach. Now, armed with fresh data for Abrysvo in ...

The Food and Drug Administration (FDA) has approved the first vaccine for pregnant women to prevent RSV in infants, the agency announced on Monday. Abrysvo has been approved as a maternal vaccine to ...

Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo has shown efficacy in immunocompromised adults, the pharma announced Monday. In substudy B of Pfizer’s ongoing Phase 3 MONeT trial, Abrysvo ...

Expectant parents could soon have another new option this fall to protect their newborns from RSV, or respiratory syncytial virus, the most common cause of hospitalization in American infants, after ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive top-line safety and immunogenicity results from substudy B of the ongoing pivotal Phase 3 clinical trial (NCT05842967) MONeT ...

The recommendation by the CHMP should now result in approval of Arexvy in the broader age range in February next year, and ...

(RTTNews) - The European Commission approved Pfizer Inc.'s (PFE) Abrysvo to help protect infants through maternal immunization and older adults from respiratory syncytial virus or RSV. It is the first ...

KIRKLAND, QC, Oct. 23, 2025 /CNW/ - Pfizer Canada is pleased to announce that ABRYSVO, its vaccine for the prevention of Respiratory Syncytial Virus (RSV), has been selected for public funding in ...

GSK said on Friday a panel of the European Medicines Agency had backed the use of its respiratory syncytial virus (RSV) ...